Abstracts tagged "Animal Model"

Abstract Number: 0087 • ACR Convergence 2024
SYNCAR: An Engineered IL-2/IL-2R-system That Selectively Enhances CD19 CAR T Cells to Deplete B Cells and Provide Therapeutic Benefit in SLE and RA Mouse Models Without Lymphodepletion
Ethan Jung¹, Marie semana¹, Ivan Cheng¹, Helena Silva¹, Sandro Vivona¹, Somya Singh¹, Michele Bauer¹, Mohammed Ali¹, Henry Rosas¹, Woei Chang¹, Deepti Rokkam¹, Patrick Lupardus¹, Martin Oft¹ and Paul-Joseph Aspuria², ¹Synthekine, Menlo Park, ²Sythekine, Menlo Park, CA
Background/Purpose: CD19 CAR-T therapy has demonstrated efficacy in autoimmune (AI) diseases like systemic lupus erythematosus (SLE) and lupus nephritis (LN), showing its potential beyond oncology.…
Abstract Number: 0950 • ACR Convergence 2024
Immunization of Arthritis Prone Mice with Malondialdehyde-Acetaldehyde (MAA) Modified Vimentin Induces Fibrotic Lung Changes
Wenxian Zhou¹, Michael Duryee², Nozima Aripova², Jill Poole², Carlos Hunter², Amy Nelson², Bryant England², Ted Mikuls² and Geoffrey Thiele², ¹University of Nebraska Medical Center, Bellevue, NE, ²University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Rheumatoid arthritis associated interstitial lung disease (RA-ILD) is the most overrepresented cause of death among RA patients, yet the mechanisms underlying lung fibrosis remain…
Abstract Number: 2597 • ACR Convergence 2024
The Stromal-cell Derived Cytokine interleukin-17D Attenuates Joint Inflammation
Jia (Sijia) Chen¹, Roopa Madhu², Catherine Manning³, Daniel Montoro⁴, Nataliya Yeremenko⁵, Kevin Wei⁶, ilya Korsunsky¹, Dominique Baeten⁵ and Ellen Gravallese⁷, ¹Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital, Brookline, MA, ³Brigham and Women's Hospital, Dedham, MA, ⁴TenSixty Biosciences, Boston, MA, ⁵Amsterdam University Medical Centers, Amsterdam, Netherlands, ⁶Brigham and Women's Hospital at Harvard Medical School, Boston, MA, ⁷Brigham and Women's Hospital, Harvard Medical School, Chestnut Hill, MA
Background/Purpose: The interleukin-17 (IL-17) family of cytokines consists of 6 evolutionarily conserved cytokines, IL-17A-F. Of these, IL-17A, B, C, and F play diverse roles in…
Abstract Number: 0088 • ACR Convergence 2024
Profound B Cell Depletion and Repopulation with Predominantly Naïve B Cells in Non-Human Primates Achieved Through a Novel In Vivo CD8-Targeted Lipid Nanoparticle mRNA CAR
Aric Frantz¹, Romina Riener¹, Annabel Wang¹, Yanjie Bao¹, Yan Zhang¹, Daiki Matsuda¹, John Li¹, David Chu¹, Theresa Hunter¹, Qian Chen Yong¹, Michelle Nguyen¹, Stuart Sievers¹, Duy Nguyen¹, Scott Roberts¹, Diana Galvan¹, Jerel Boyd Vega¹, Matthew Butcher¹, Stanley Zhang¹, Stephen Flynn¹, Yi Kuo¹, Steven Tanis¹, John Scholler², Gregor Adams¹, Michael Rosenzweig¹, Priya Karmali¹, Adrian Bot¹, Carl June² and Haig Aghajanian¹, ¹Capstan Therapeutics, San Diego, CA, ²University of Pennsylvania Perelman School of Medicine, Philadelphia, PA

Background/Purpose: Ex vivo chimeric antigen receptor (CAR) T cell therapies have revolutionized cancer treatment and are demonstrating durable clinical efficacy in various autoimmune disease indications.…
Abstract Number: 0955 • ACR Convergence 2024
Inhibition of Interleukin-2-Inducible T Cell Kinase with Soquelitinib Demonstrates Efficacy in Preventing Lung Damage in Murine Models of Systemic Sclerosis
Goncalo Boleto¹, Anne Cauvet², James Rose³, Lih-Yun Hsu³, Richard A. Miller³ and Yannick Allanore⁴, ¹Rheumatology Department, Unidade Local de Saúde Santa Maria, Centro Académico de Medicina de Lisboa, Lisboa, Portugal., Lisbon, Portugal, ²Université de Paris, Institut Cochin, INSERM U1016 CNRS UMR8104, Paris, France, ³Corvus Pharmaceuticals, 863 Mitten Road, Burlingame, Burlingame, CA, ⁴Université Paris Cité, Paris, France
Background/Purpose: T cells abnormal activation plays a pivotal role in the early inflammatory stages of systemic sclerosis (SSc). Compelling evidence supports that SSc has a…
Abstract Number: 2603 • ACR Convergence 2024
A Human Lupus Gut Pathobiont Accelerates Systemic Inflammation, Autoantibody Production and T Cell Dysregulation
Gregg Silverman¹ and Laurence Morel², ¹NYU Grossman School of Medicine, New York, NY, ²Joe R. & Teresa Lozano Long School of Medicine, San Antonio, TX
Background/Purpose: The mechanisms by which the gut microbiome contributes to autoimmune pathogenesis remain poorly understood. In lupus patients, more than ten-fold blooms of Ruminococcus gnavus…
Abstract Number: 0090 • ACR Convergence 2024
Parenchymal and Hematopoietic IFNγ Signaling Exhibits Dichotomous Effects in Murine Lupus
Minjung Kim¹, Anthony Marinov², Haylee Cosgrove³, Xiaoyan Gong³, Mark Shlomchik³ and Jeremy Tilstra³, ¹University of Illinois College of Medicine at Chicago, Chicago, IL, ²University of Pittsburgh, Homestead, PA, ³University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Lupus nephritis is the most common life-threatening end-organ complication of SLE, and response rates to current interventions remain poor. Notably, PD-L1 and other interferon-responsive…
Abstract Number: 0959 • ACR Convergence 2024
Radiomics Non-Invasively Conveys Time-Resolved Molecular Pathway Activity in Experimental Fibrosing Interstitial Lung Disease
David Lauer¹, Matthias Brunner², Hubert Gabrys³, Kerstin Klein², Oliver Distler⁴, Britta Maurer⁵ and Janine Gote-Schniering², ¹University Hospital Bern, Bern, Switzerland, ²University of Bern, Bern, Switzerland, ³University Hospital Zurich, Zurich, Zurich, Switzerland, ⁴Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, Zurich, Switzerland, ⁵University Hospital Bern, University Bern, Bern, Switzerland
Background/Purpose: Interstitial lung disease (ILD) is a major cause of mortality in patients with autoimmune-related CTD such as SSc and RA. Molecular characterization of the…
Abstract Number: 2662 • ACR Convergence 2024
In Vivo Generation of B Cell Depleting CAR T Cell Therapies for Treatment of Autoimmune Diseases
Laurie Beitz¹, Maura Parker¹, Justin Ulrich-Lewis¹, Kristen Mittelsteadt¹, Rebecca Gottschalk¹, Chris Nicolai¹, Jim Qin¹, Andrew Scharenberg¹, Ryan Larson¹, Byoung Ryu¹, Eric Cavanaugh², Weiliang Tang¹, Seungjin Shin¹, Kelsey Lynch¹ and Hans-Peter Kiem², ¹Umoja Biopharma, Seattle, WA, ²Fred Hutch Cancer Research Center, Seattle, WA
Background/Purpose: CAR T cell therapy promises to revolutionize the treatment of hematologic malignancies, and more recently has generated early data that it may afford long…
Abstract Number: 0094 • ACR Convergence 2024
Small GTPase Rab4A Regulates Mouse Behavior Through Altered Serum Serotonin Levels and Microglial mTORC1 Activation in Lupus-prone B6.TC Mice
Thomas Winans¹, Xiaojing Wang², Joshua Lewis², Jessica Nolan¹, Laurence Morel³ and Andras Perl⁴, ¹SUNY Upstate Medical University, Syracuse, ²SUNY Upstate Medical University, Syracuse, NY, ³University of Texas health San Antonio, San Antonio, TX, ⁴SUNY, Syracuse, NY
Background/Purpose: Rab4A is a small GTPase that is overexpressed in patients and mice with systemic lupus erythematosus (SLE, PubMed ID: 23897774; PubMed ID 31805010). Rab4A…
Abstract Number: 0964 • ACR Convergence 2024
Engaging the PD-1 Pathway Attenuates Inflammation Associated Fibrosis in Systemic Sclerosis Fibroblasts and a Preclinical Mouse Model
Maithri Aspari¹, Voon Ong², Klaus Soendergaard³, Esben Naeser⁴, Malene Hvid⁴, Angela Tam⁵, Shiwen Xu⁵, Christopher Denton⁶, David Abraham⁷, Bent Deleuran¹ and Stinne Greisen⁸, ¹Aarhus University, Aarhus, Denmark, ²University College London, London, England, United Kingdom, ³Aarhus University Hospital, Aarhus, Denmark, ⁴AARHUS UNIVERSITET, AARHUS C, Denmark, ⁵University College London, London, United Kingdom, ⁶University College London, Northwood, United Kingdom, ⁷UCL, London, United Kingdom, ⁸Aarhus University/Aarhus University Hospital, Aarhus, Denmark
Background/Purpose: The precise molecular mechanisms driving fibrosis in diffuse cutaneous systemic sclerosis (dcSSc) remain to be elucidated. The immune regulatory programmed cell death protein 1…
Abstract Number: 0097 • ACR Convergence 2024
The Human Lupus TREX1 D18N Mutation Engineered in C. Elegans Leads to Cell Death. What Can We Learn About Lupus Using C. Elegans?
Htay Htay Kyi¹, Patricia Barreto², Yeshaswi Pulijala³, Thejasvi Venkatachalam³ and Martha Soto², ¹Rutgers New Jersey Medical School, Jersey City, NJ, ²Robert Wood Johnson Medical School, Piscataway, NJ, ³RWJ-PATHOLOGY-RESEARCH-PISC, Piscataway
Background/Purpose: TREX1 gene encodes the three prime repair exonuclease 1 enzyme that degrades DNA. TREX1 plays a key role in genomic DNA degradation, cell death…
Abstract Number: 0971 • ACR Convergence 2024
Ligand-Receptor Analysis Reveals Myeloid-Mediated Pro-Inflammatory Responses and Loss of Mesenchymal Signaling Driven by TNFR1 in Experimental Pulmonary Hypertension
Gaochan Wang¹, Stacey Duemmel² and Benjamin Korman³, ¹University of Rochester School of Medicine and Dentistry, Rochester, NY, ²URMC, UNIVERSITY OF ROCHESTER, Rochester, NY, ³University of Rochester, Rochester, NY
Background/Purpose: Pulmonary hypertension (PH) is a severe, progressive disorder characterized by elevated pulmonary artery pressures, right ventricular hypertrophy, and increased mortality which is a severe…
Abstract Number: 0281 • ACR Convergence 2024
Intra-articular Treatment Combining Sustained Release Colchicine Encapsulated in Microspheres, and Ropivacaine, Is Effective in Inflammatory Arthritis in Rats
Julien GRASSOT¹, Farah MARZOUKI², Roxane HERVE³, Magali BECKLER⁴, Luca SEMERANO⁵, Natacha BESSIS⁶, Elodie RIVIERE⁷, Charles SANSON², Gauthier POULIQUEN², Philippe POULETTY⁸ and Marie-Christophe BOISSIER⁹, ¹PK MED, LYON, Rhone-Alpes, France, ²PK MED, LYON, France, ³INSERM U1125, Bobigny, France, ⁴INSERM 1125, Bobigny, France, ⁵Avicenne Teaching Hospital APHP, Bobigny, France, ⁶INSERM, Université Sorbonne Paris Nord, PARIS, France, ⁷INSERM, Université Sorbonne Paris Nord, APHP, PARIS, France, ⁸PK MED, PARIS, France, ⁹University Sorbonne Paris Nord, Bobigny, France
Background/Purpose: Gout is a common disease with a prevalence and incidence on the rise worldwide. However, approved treatments to treat acute gout flares have slow…
Abstract Number: 1430 • ACR Convergence 2024
C57BL/6.NOD-Aec1Aec2 Mice Recapitulate Sjögren’s Serology Better Than NOD.B10Sn-H2b Models and JAK Inhibitor Treatment Improves Immunoglobulins and Salivary Gland Inflammation but Not Salivary Flow in Sjögren’s Mice
Sara McCoy¹ and Ilya Gurevic², ¹University of Wisconsin, Middleton, WI, ²University of Wisconsin, Madison
Background/Purpose: Sjögren’s disease (SjD) is a systemic autoimmune disease in which interferons (IFNs) are believed to play a major role/ JAK inhibitors (JAKinibs) block IFN…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].